Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents

Oyama, Tsuksa; Sykes, Kathryn; Samli, Kausar N.; Minna, John D.; Johnston, Stephen Albert; Brown, Kathlynn C.

doi:10.1016/j.canlet.2003.08.011

Cited by 112 publications

(137 citation statements)

References 48 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…Ex vivo phage library panning on primary rat islets. The panning procedure was modified from previously published protocols (8,14) for use with freshly isolated islets. Preclearing of cell surface receptors was not necessary since islets were isolated in serum-free media.…”

Section: Methodsmentioning

confidence: 99%

“…Targeting to islets is made challenging by the fact that these cells in aggregate represent only 2% by weight of the entire pancreas (12). We have previously demonstrated that phage panning can be carried out on cells in culture to obtain peptides that mediate specific binding to the target cells while not binding to undesired cell types (8,(13)(14)(15)(16)(17). The high discriminating power of the selected phage suggests that peptides could be identified that specifically bind to ␤-cells within the pancreas.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Peptide-Mediated Targeting of the Islets of Langerhans

et al. 2005

Self Cite

View full text Add to dashboard Cite

Strategies for restoring ␤-cell function in diabetic patients would be greatly aided by the ability to target genes, proteins, or small molecules specifically to these cells. Furthermore, the ability to direct imaging agents specifically to ␤-cells would facilitate diagnosis and monitoring of disease progression. To isolate ligands that can home to ␤-cells in vivo, we have panned a random phage-displayed 20-mer peptide library on freshly isolated rat islets. We have isolated two 20-mer peptides that bind to islets ex vivo. One of these peptides preferentially homes to the islets of Langerhans in a normal rat with clear differentiation between the endocrine and exocrine cells of the pancreas. Furthermore, this peptide does not target ␤-cells in a type 2 diabetes animal model, suggesting that the peptide can discriminate between glucose-stimulated insulin secretion-functional and -dysfunctional ␤-cells. Diabetes 54: 2103-2108, 2005

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Peptide-Mediated Targeting of the Islets of Langerhans

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…77 Tissue-specific homing peptides have also been reported for pancreatic β cells, 78 as well as specific peptides for tumor cells, especially lung tumor. 65,79 There is also a known peptide sequence, designated as GE11, which recognizes the EGFR. 80 Tumor-homing peptides have already entered clinical trials.…”

Section: Peptidesmentioning

confidence: 99%

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Toporkiewicz¹,

Meissner²,

Matusewicz³

et al. 2015

IJN

View full text Add to dashboard Cite

There are many problems directly correlated with the systemic administration of drugs and how they reach their target site. Targeting promises to be a hopeful strategy as an improved means of drug delivery, with reduced toxicity and minimal adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, either directly or as carriers for a drug, for specific retention and uptake by the targeted diseased cells. One of the most important parameters which should be taken into consideration in the selection of an appropriate ligand for targeting is the binding affinity ( K D ). In this review we focus on the importance of binding affinities of monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small targeting molecules in the process of selection of the most suitable ligand for targeting of nanoparticles. In order to provide a critical comparison between these various options, we have also assessed each technology format across a range of parameters such as molecular size, immunogenicity, costs of production, clinical profiles, and examples of the level of selectivity and toxicity of each. Wherever possible, we have also assessed how incorporating such a targeted approach compares with, or is superior to, original treatments.

show abstract

“…The method is used for various applications, such as mapping and mimicking of epitopes, identifying new receptors and natural ligands, identifying high-affinity antibodies and analogues, isolating specific antigens that bind to bioactive compounds, producing novel enzyme inhibitors and DNA-binding proteins and probing cellular and tissue-specific processes. Phage display was successfully applied for the identification of novel peptides with high specificity [27,28] and has been employed to isolate an NG2 proteoglycan-binding peptide to target tumour neovasculature [29] or to identify specifically binding peptides for human lung carcinoma, mammary carcinoma, prostate carcinoma and neuroblastoma cells [30][31][32][33][34].…”

Section: Phage Displaymentioning

confidence: 99%